Research programme: off the shelf cell therapies - BrainChild Bio
Latest Information Update: 31 Jul 2025
At a glance
- Originator BrainChild Bio
- Class Antineoplastics; Cell therapies; Immunoproteins
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical CNS cancer
Most Recent Events
- 31 Jul 2025 Preclinical trials in CNS cancer in USA (Parenteral), before July 2025 (BrainChild Bio pipeline, July 2025)